These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19337531)

  • 1. Peripheral artery disease: potential role of ACE-inhibitor therapy.
    Coppola G; Romano G; Corrado E; Grisanti RM; Novo S
    Vasc Health Risk Manag; 2008; 4(6):1179-87. PubMed ID: 19337531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.
    Hirsch AT; Duprez D
    Vasc Med; 2003 Nov; 8(4):273-8. PubMed ID: 15125489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?
    Remme WJ
    Drugs; 1997; 54 Suppl 5():59-70. PubMed ID: 9429846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and peripheral arterial disease: potential mechanisms and clinical benefits.
    Alnaeb ME; Alobaid N; Seifalian AM; Mikhailidis DP; Hamilton G
    Ann Vasc Surg; 2006 Sep; 20(5):696-705. PubMed ID: 16841271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization.
    Thiney M; Della Schiava N; Ecochard R; Feugier P; Lermusiaux P; Millon A; Long A
    Ann Vasc Surg; 2018 Oct; 52():138-146. PubMed ID: 29777848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
    Hornig B; Arakawa N; Drexler H
    Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the preventive effect of different drugs depend on location of the atherosclerotic process?
    Poredos P; Jezovnik MK
    Int Angiol; 2008 Aug; 27(4):274-80. PubMed ID: 18677288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease.
    Thiney M; Della Schiava N; Feugier P; Lermusiaux P; Ninet J; Millon A; Long A
    Ann Vasc Surg; 2017 Apr; 40():85-93. PubMed ID: 27908822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
    Al-Omran M; Lindsay TF
    Can J Cardiol; 2005 Feb; 21(2):189-93. PubMed ID: 15729421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of endothelial enzymes: new therapeutic targets.
    López-Jaramillo P; Casas JP
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S100-3. PubMed ID: 11986905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.
    Ruilope LM; Redón J; Schmieder R
    Vasc Health Risk Manag; 2007; 3(1):1-9. PubMed ID: 17583170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.